Computationally Redesigned Skin-Penetrating Peptide Delivers Cancer Drug Through Skin to Shrink Tumors
A computationally optimized cell-penetrating peptide (589WP) significantly improved transdermal delivery and inhibited melanoma growth when conjugated to the anti-cancer drug floxuridine.
Quick Facts
What This Study Found
Computationally redesigned penetratin derivative (589WP) significantly improved transdermal delivery and, when conjugated to floxuridine in a topical gel, outperformed higher doses of free drug in melanoma inhibition without skin toxicity.
Key Numbers
How They Did This
CPP screening, computational simulation to identify permeability determinants, peptide redesign, in vitro skin permeability studies, in vivo fluorescence imaging, peptide-drug conjugation via ester linkage, and topical melanoma treatment model.
Why This Research Matters
Topical cancer treatment could avoid the systemic side effects of intravenous chemotherapy. This computationally designed peptide delivery system demonstrates the feasibility of skin-penetrating peptide-drug conjugates.
The Bigger Picture
This computational prediction and design approach for skin-penetrating peptides could be applied broadly to improve transdermal delivery of many drugs beyond cancer therapy.
What This Study Doesn't Tell Us
Melanoma mouse model only. Ester linkage may limit conjugate stability. Manufacturing scalability of peptide-drug conjugates needs assessment. Skin penetration depth may be insufficient for deep tumors.
Questions This Raises
- ?Could this peptide delivery approach work for drugs treating other skin conditions?
- ?How does 589WP penetration depth compare across different skin types?
- ?Can the computational prediction model be applied to design peptides for mucosal delivery?
Trust & Context
- Key Stat:
- Beat higher-dose free drug Peptide-drug conjugate gel inhibited melanoma more effectively than higher doses of unconjugated drug
- Evidence Grade:
- Preclinical study with computational design, in vitro/in vivo validation, and efficacy in tumor model. Novel platform needing clinical development.
- Study Age:
- Published in 2025.
- Original Title:
- Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma.
- Published In:
- Acta pharmaceutica Sinica. B, 16(2), 1140-1154 (2026)
- Authors:
- Du, Sanjiang, Wang, Hanlin, Geng, Feiyang, Zhang, Zongxu, Liu, Chenghao, Lu, Weiyue, Wei, Gang
- Database ID:
- RPEP-15123
Evidence Hierarchy
Frequently Asked Questions
How does a peptide help deliver drugs through skin?
Cell-penetrating peptides can pass through the skin barrier by interacting with cell membranes. By conjugating a drug to an optimized skin-penetrating peptide, the drug is carried across the skin barrier and delivered directly to the target tissue.
Could this replace injections for skin cancer treatment?
Potentially. This study shows a topical gel with a peptide-drug conjugate effectively shrank skin tumors in mice. If validated in humans, it could provide a painless, non-invasive alternative to injections or surgery for some skin cancers.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15123APA
Du, Sanjiang; Wang, Hanlin; Geng, Feiyang; Zhang, Zongxu; Liu, Chenghao; Lu, Weiyue; Wei, Gang. (2026). Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma.. Acta pharmaceutica Sinica. B, 16(2), 1140-1154. https://doi.org/10.1016/j.apsb.2025.12.026
MLA
Du, Sanjiang, et al. "Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma.." Acta pharmaceutica Sinica. B, 2026. https://doi.org/10.1016/j.apsb.2025.12.026
RethinkPeptides
RethinkPeptides Research Database. "Skin-penetrating peptides derived from computational simulat..." RPEP-15123. Retrieved from https://rethinkpeptides.com/research/du-2026-skinpenetrating-peptides-derived-from
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.